Christi Shaw (Kite)

Gilead­'s land­mark CAR-T ap­proval leaves Bris­tol My­ers Squibb scram­bling for sec­ond place

You’ve got to be quick­er than that, Bris­tol My­ers Squibb. Gilead’s Kite scored a land­mark ap­proval for Yescar­ta in large B-cell lym­phoma (LB­CL) on Fri­day, mak­ing it the first CAR-T avail­able in the sec­ond-line lym­phoma set­ting.

The news comes just a few months ahead of an ex­pect­ed de­ci­sion for BMS’ CAR-T ri­val Breyanzi in the same in­di­ca­tion. Gilead says the ap­proval should rough­ly dou­ble Yescar­ta’s mar­ket size in the US — a mile­stone Kite CEO Christi Shaw said has been “years in the mak­ing.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.